General Information of Drug (ID: DMRL3AB)

Drug Name
Famotidine
Synonyms
Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Indication
Disease Entry ICD 11 Status REF
Gastric ulcer DA60 Approved [1]
Gastrinoma 2C10.1 Approved [1]
Peptic esophagitis N.A. Approved [1]
Peptic ulcer DA61 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 337.5
Logarithm of the Partition Coefficient (xlogp) -0.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 6.6 mL/min/kg [5]
Elimination
67% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.8 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.97661 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.84% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Bone marrow failure Not Available IL3 OT0CQ35N [7]
Bone marrow failure Not Available CSF2 OT1M7D28 [7]
Bone marrow failure Not Available CSF3R OTXRAY6X [7]
Chemical Identifiers
Formula
C8H15N7O2S3
IUPAC Name
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Canonical SMILES
C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
InChI
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChIKey
XUFQPHANEAPEMJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5702160
ChEBI ID
CHEBI:4975
CAS Number
76824-35-6
DrugBank ID
DB00927
TTD ID
D0K0OZ
VARIDT ID
DR00278
INTEDE ID
DR0680
ACDINA ID
D00518
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [9]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [10]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME
DEGTFWK CP2CJ_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Gene/Protein Processing [12]
Fibroblast growth factor 21 (FGF21) OT3RXVRD FGF21_HUMAN Gene/Protein Processing [13]
Gastrin (GAST) OTD0IP9N GAST_HUMAN Gene/Protein Processing [14]
Granulocyte colony-stimulating factor receptor (CSF3R) OTXRAY6X CSF3R_HUMAN Drug Response [7]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Drug Response [7]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Gene/Protein Processing [15]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB) OT17HGXJ DMB_HUMAN Gene/Protein Processing [15]
Interleukin-3 (IL3) OT0CQ35N IL3_HUMAN Drug Response [7]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Regulation of Drug Effects [9]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Gene/Protein Processing [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Famotidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Famotidine due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [17]
Cefuroxime DMSIMD8 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Cefuroxime. Acute bronchitis [CA42] [18]
Glibenclamide DM8JXPZ Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Glibenclamide. Acute diabete complication [5A2Y] [19]
Glipizide DMZA5PQ Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Glipizide. Acute diabete complication [5A2Y] [19]
Ivosidenib DM8S6T7 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Ivosidenib. Acute myeloid leukaemia [2A60] [20]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Famotidine and Midostaurin. Acute myeloid leukaemia [2A60] [20]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Famotidine and Idarubicin. Acute myeloid leukaemia [2A60] [20]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Famotidine and Gilteritinib. Acute myeloid leukaemia [2A60] [20]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Famotidine and Oliceridine. Acute pain [MG31] [20]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Famotidine and Rivastigmine. Alzheimer disease [8A20] [21]
Bepridil DM0RKS4 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Bepridil. Angina pectoris [BA40] [20]
Dronedarone DMA8FS5 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Dronedarone. Angina pectoris [BA40] [20]
Bedaquiline DM3906J Moderate Increased risk of prolong QT interval by the combination of Famotidine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Famotidine and Cilostazol. Arterial occlusive disease [BD40] [20]
Posaconazole DMUL5EW Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Posaconazole. Aspergillosis [1F20] [22]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Levalbuterol. Asthma [CA23] [20]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Pirbuterol. Asthma [CA23] [20]
Aminophylline DML2NIB Moderate Decreased metabolism of Famotidine caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [23]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Famotidine and Salbutamol. Asthma [CA23] [20]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Famotidine and Formoterol. Asthma [CA23] [20]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [20]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Famotidine and Desipramine. Attention deficit hyperactivity disorder [6A05] [20]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Ofloxacin. Bacterial infection [1A00-1C4Z] [20]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Famotidine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [21]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Famotidine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [20]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Norfloxacin. Bacterial infection [1A00-1C4Z] [20]
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [18]
Bacampicillin DMP54C7 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Famotidine and Levofloxacin. Bacterial infection [1A00-1C4Z] [20]
Cefditoren DMSUVM1 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Cefditoren. Bacterial infection [1A00-1C4Z] [24]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [20]
Vismodegib DM5IXKQ Minor Decreased absorption of Famotidine due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [20]
Pexidartinib DMS2J0Z Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [25]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Famotidine and Eribulin. Breast cancer [2C60-2C6Y] [20]
Lapatinib DM3BH1Y Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Lapatinib. Breast cancer [2C60-2C6Y] [26]
HKI-272 DM6QOVN Major Decreased absorption of Famotidine due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [20]
Bosutinib DMTI8YE Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [26]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Famotidine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [20]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [20]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [20]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Famotidine and Isoproterenol. Conduction disorder [BC63] [20]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Halothane. Corneal disease [9A76-9A78] [20]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Sevoflurane. Corneal disease [9A76-9A78] [20]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Famotidine and Probucol. Coronary atherosclerosis [BA80] [20]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Famotidine caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [23]
Pasireotide DMHM7JS Moderate Increased risk of prolong QT interval by the combination of Famotidine and Pasireotide. Cushing syndrome [5A70] [20]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Famotidine and Osilodrostat. Cushing syndrome [5A70] [20]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Famotidine and Clomipramine. Depression [6A70-6A7Z] [20]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Famotidine and Doxepin. Depression [6A70-6A7Z] [20]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Famotidine and Maprotiline. Depression [6A70-6A7Z] [20]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Famotidine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [20]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Famotidine and Deutetrabenazine. Dystonic disorder [8A02] [20]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Famotidine and Ingrezza. Dystonic disorder [8A02] [20]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Famotidine and Solifenacin. Functional bladder disorder [GC50] [20]
Itraconazole DMCR1MV Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Itraconazole. Fungal infection [1F29-1F2F] [27]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [28]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Famotidine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [20]
GS-5885 DMSL3DX Moderate Decreased absorption of Famotidine due to altered gastric pH caused by GS-5885. Hepatitis virus infection [1E50-1E51] [29]
Fosamprenavir DM4W9B3 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Fosamprenavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Famotidine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [20]
Saquinavir DMG814N Moderate Increased risk of prolong QT interval by the combination of Famotidine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [20]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [20]
Rilpivirine DMJ0QOW Major Decreased absorption of Famotidine due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [31]
Atazanavir DMSYRBX Major Decreased absorption of Famotidine due to altered gastric pH caused by Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [26]
Raltegravir DMYURI6 Minor Decreased absorption of Famotidine due to altered gastric pH caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [32]
Probenecid DMMFWOJ Minor Decreased elimination of Famotidine caused by Probenecid mediated competitive inhibition of renal tubular secretion. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [33]
Ramelteon DM7IW9J Moderate Decreased metabolism of Famotidine caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [34]
Crizotinib DM4F29C Moderate Increased risk of prolong QT interval by the combination of Famotidine and Crizotinib. Lung cancer [2C25] [20]
Ceritinib DMB920Z Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [35]
Dacomitinib DMOH8VY Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Dacomitinib. Lung cancer [2C25] [26]
Osimertinib DMRJLAT Moderate Increased risk of prolong QT interval by the combination of Famotidine and Osimertinib. Lung cancer [2C25] [20]
Selpercatinib DMZR15V Major Decreased absorption of Famotidine due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [26]
Lumefantrine DM29GAD Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lumefantrine. Malaria [1F40-1F45] [20]
Halofantrine DMOMK1V Moderate Increased risk of prolong QT interval by the combination of Famotidine and Halofantrine. Malaria [1F40-1F45] [20]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Famotidine and Hydroxychloroquine. Malaria [1F40-1F45] [20]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Famotidine and Primaquine. Malaria [1F40-1F45] [20]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [20]
Arsenic trioxide DM61TA4 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [20]
Acalabrutinib DM7GCVW Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [36]
Ponatinib DMYGJQO Minor Decreased absorption of Famotidine due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [20]
Vemurafenib DM62UG5 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Vemurafenib. Melanoma [2C30] [20]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Famotidine and LGX818. Melanoma [2C30] [20]
Dabrafenib DMX6OE3 Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Dabrafenib. Melanoma [2C30] [20]
Panobinostat DM58WKG Moderate Increased risk of prolong QT interval by the combination of Famotidine and Panobinostat. Multiple myeloma [2A83] [20]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Famotidine and Thalidomide. Multiple myeloma [2A83] [20]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Famotidine and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Famotidine and Fingolimod. Multiple sclerosis [8A40] [37]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Famotidine and Ozanimod. Multiple sclerosis [8A40] [38]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Famotidine and Romidepsin. Mycosis fungoides [2B01] [20]
Nilotinib DM7HXWT Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Nilotinib. Myeloproliferative neoplasm [2A20] [20]
Dasatinib DMJV2EK Major Decreased absorption of Famotidine due to altered gastric pH caused by Dasatinib. Myeloproliferative neoplasm [2A20] [39]
Prasugrel DM7MT6E Minor Decreased absorption of Famotidine due to altered gastric pH caused by Prasugrel. Myocardial infarction [BA41-BA43] [40]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Famotidine and Promethazine. Nausea/vomiting [MD90] [20]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Famotidine and Entrectinib. Non-small cell lung cancer [2C25] [20]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lofexidine. Opioid use disorder [6C43] [20]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Rucaparib. Ovarian cancer [2C73] [20]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Famotidine and Triclabendazole. Parasitic worm infestation [1F90] [20]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Famotidine and Pimavanserin. Parkinsonism [8A00] [20]
Lefamulin DME6G97 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lefamulin. Pneumonia [CA40] [20]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Famotidine and Degarelix. Prostate cancer [2C82] [20]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Famotidine and ABIRATERONE. Prostate cancer [2C82] [20]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Famotidine and Enzalutamide. Prostate cancer [2C82] [20]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Famotidine and Relugolix. Prostate cancer [2C82] [20]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Famotidine and Bicalutamide. Prostate cancer [2C82] [20]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Famotidine and Levomepromazine. Psychotic disorder [6A20-6A25] [20]
Axitinib DMGVH6N Minor Decreased absorption of Famotidine due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [41]
Gatifloxacin DMSL679 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [20]
Mesoridazine DM2ZGAN Moderate Increased risk of prolong QT interval by the combination of Famotidine and Mesoridazine. Schizophrenia [6A20] [20]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Famotidine and Aripiprazole. Schizophrenia [6A20] [20]
Iloperidone DM6AUFY Moderate Increased risk of prolong QT interval by the combination of Famotidine and Iloperidone. Schizophrenia [6A20] [20]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Famotidine and Paliperidone. Schizophrenia [6A20] [20]
Amisulpride DMSJVAM Moderate Increased risk of prolong QT interval by the combination of Famotidine and Amisulpride. Schizophrenia [6A20] [20]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Asenapine. Schizophrenia [6A20] [20]
Pimozide DMW83TP Moderate Increased risk of prolong QT interval by the combination of Famotidine and Pimozide. Schizophrenia [6A20] [20]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Famotidine and LEE011. Solid tumour/cancer [2A00-2F9Z] [20]
Vandetanib DMRICNP Moderate Increased risk of prolong QT interval by the combination of Famotidine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [20]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Famotidine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [20]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Famotidine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Famotidine and Pitolisant. Somnolence [MG42] [20]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Famotidine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [20]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Lenvatinib. Thyroid cancer [2D10] [20]
Tolbutamide DM02AWV Moderate Decreased absorption of Famotidine due to altered gastric pH caused by Tolbutamide. Type 2 diabetes mellitus [5A11] [19]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Famotidine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [20]
Procainamide DMNMXR8 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Procainamide. Ventricular tachyarrhythmia [BC71] [20]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Famotidine and Propafenone. Ventricular tachyarrhythmia [BC71] [20]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Famotidine and Flecainide. Ventricular tachyarrhythmia [BC71] [20]
Amiodarone DMUTEX3 Moderate Increased risk of prolong QT interval by the combination of Famotidine and Amiodarone. Ventricular tachyarrhythmia [BC71] [20]
⏷ Show the Full List of 128 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
Xanthan gum E00694 Not Available Bioadhesive material; Emulsifying agent; Gelling agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Famotidine 20 mg tablet 20 mg Chewable Tablet Oral
Famotidine 40mg/5ml for suspension 40mg/5ml For Suspension Oral
Famotidine 10mg/ml injectable 10mg/ml Injectable Injection
Famotidine 20mg tablet 20mg Tablet Oral
Famotidine 10 mg tablet 10 mg Oral Tablet Oral
Famotidine 20 mg tablet 20 mg Oral Tablet Oral
Famotidine 40 mg tablet 40 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Famotidine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7074).
3 ClinicalTrials.gov (NCT04370262) Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
9 Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
10 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
11 Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
12 Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3/-catenin signaling pathway in the SH-SY5Y cell line. Chem Biol Interact. 2019 Dec 1;314:108823. doi: 10.1016/j.cbi.2019.108823. Epub 2019 Sep 26.
13 Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. J Clin Gastroenterol. 1995;21 Suppl 1:S24-9.
14 Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
15 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
16 Hyperprolactinaemia during famotidine therapy. Lancet. 1993 Oct 2;342(8875):868. doi: 10.1016/0140-6736(93)92729-d.
17 Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
18 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
19 Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
20 Cerner Multum, Inc. "Australian Product Information.".
21 Canadian Pharmacists Association.
22 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
23 Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
24 Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
25 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27 Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
28 Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
29 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
30 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
31 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
32 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
33 Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T "The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers." J Clin Pharmacol 30 (1990): 50-6. [PMID: 2303581]
34 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
35 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
38 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
40 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
41 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.